
    
      Patients will receive weekly 3 doses of CAR2 Anti-CEA CAR-T cells in each 28-day cycle by
      hepatic arterial infusions using a Pressure Enhanced Delivery Device (PEDD) with low dose
      systemic IL-2 support. Patients may receive up to 3 cycles of CAR2 Anti-CEA CAR-T cell
      hepatic arterial infusions, per discretion of the investigator.

      All patients who receive investigational CAR-T therapy will be included in the analyses and
      summaries of safety, efficacy, pharmacokinetic, and pharmacodynamic assessments.
    
  